Compare SOS & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SOS | ICU |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7M | 9.1M |
| IPO Year | 2005 | N/A |
| Metric | SOS | ICU |
|---|---|---|
| Price | $1.30 | $2.44 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 16.6K | ★ 68.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1,043.70 |
| Revenue Next Year | N/A | $54.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.02 | $0.22 |
| 52 Week High | $8.92 | $2.98 |
| Indicator | SOS | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 36.49 | 57.84 |
| Support Level | $1.17 | $2.37 |
| Resistance Level | $1.39 | $2.49 |
| Average True Range (ATR) | 0.14 | 0.18 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 11.70 | 36.27 |
SOS Ltd is a multifaceted company that leverages the power of data to provide marketing solutions, while also participating in the burgeoning fields of blockchain and cryptocurrency operations, as well as commodity trading. Its product offerings are diversified across four main areas: commodity trading, insurance marketing, cryptocurrency mining, and other services. The company has three reporting segments: Commodity trading, Cryptocurrency mining, and Others. Key revenue is generated from Commodity trading.
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.